Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen-Reference-Cited by-同舟云学术

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

Published:2017-08-26 Issue:4 Volume:66 Page:1083-1089
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Gane Edward J.¹,Shiffman Mitchell L.²,Etzkorn Kyle³,Morelli Giuseppe⁴,Stedman Catherine A.M.⁵,Davis Mitchell N.⁶,Hinestrosa Federico⁷,Dvory-Sobol Hadas⁸,Huang K.C.⁸,Osinusi Anu⁸,McNally John⁸,Brainard Diana M.⁸,McHutchison John G.⁸,Thompson Alex J.⁹,Sulkowski Mark S.¹⁰,

Affiliation:

1. Auckland Clinical Studies; Auckland New Zealand

2. Liver Institute of Virginia; Richmond VA

3. Borland Groover Clinic; Jacksonville FL

4. University of Florida; Gainesville FL

5. Christchurch Hospital and University of Otago; Christchurch New Zealand

6. South Florida Center of Gastroenterology; Wellington FL

7. Orlando Immunology Center; Orlando FL

8. Gilead Sciences, Inc; Foster City CA

9. St. Vincent's Hospital; Melbourne Australia

10. Johns Hopkins University School of Medicine; Baltimore MD

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Reference10 articles.

1. Interferon-free combination therapies for the treatment of hepatitis C: current insights;Holmes;Hepat Med,2015

2. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment;Lam;Therap Adv Gastroenterol,2015

3. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel HCV guidance: recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org 2016

4. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens;Pawlotsky;Gastroenterology,2016

5. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir;Sarrazin;Gastroenterology,2016

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis;Digestive Diseases and Sciences;2024-04-05

2. Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs;Egyptian Liver Journal;2024-03-11

3. Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan;Problems of Virology;2023-07-06

4. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C;Russian Journal of Gastroenterology, Hepatology, Coloproctology;2023-06-04

5. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks;Journal of Clinical Virology Plus;2023-06